High Tide Inc.

HITI Healthcare Pharmaceutical Retailers

High Tide Inc.’s revenue for fiscal 2025 (year ended October 2025) was $424.0 million, up 10.5% from fiscal 2024. In the quarter to July 2026, revenue grew 30.7%, EPS grew 800.0%, free cash flow fell 7.91% and total debt rose 54.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

2.57 0.01 +0.39%
Market cap
$228.2M
P/E
0.0×
Fwd P/E
92.0×
Dividend yield
—
F-score
2/9
Altman Z
1.52
Beneish M
−3.01
Dividend safety
25/100

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 11.39%

Capital & Financial Ratios $m

Market Cap 228.20
Revenue 519.66
Net Income (24.39)
Free Cash Flow 11.14
Net Debt 45.73
Current Ratio 1.50
Debt/Equity 0.93
P/E ratio 0.00
Fwd P/E 92.00 (above 35: high)
P/S ratio 0.43
P/B ratio 2.63
Past 5Y EPS Growth —
This Y EPS Growth 127.19% (at or above 15%: strong)
Next Y EPS Growth 10.36%
Next Y revenue growth 24.90% (at or above 10%: strong)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/S against its own 10 years 36.32%
10-year low 10-year high
P/B against its own 10 years 60.43%
10-year low 10-year high
EV/Sales against its own 10 years 42.28%
10-year low 10-year high
EV/FCF against its own 10 years 79.15%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 22 35 34 34
Receivables 6 2 4 7
Inventory 19 22 48 48
Other — — — —
51 63 98 105
2023 2024 2025 Q'26
Payables 15 17 34 38
ST’ Debt 18 9 12 10
Other 3 — 7 3
43 45 71 70

Compound Annual Growth %

10y 5y 3y
Sales — 46.92% 15.22%
Cash Flow — 20.95% 69.61%
Earnings — 0.00% 0.00%
Book Value — 53.11% (16.46%)

Revenue $m

Jan Apr Jul Oct Year
’26 129 131 142 — —
’25 100 97 109 118 424
’24 95 92 96 101 384
’23 88 89 93 92 362
’22 57 64 74 82 277
’21 30 32 39 43 144
’20 10 14 17 20 62
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jan Apr Jul Oct Year
’26 4 3 7 — —
’25 0 6 8 3 17
’24 5 9 4 7 26
’23 2 1 6 7 15
’22 (1) (2) 0 6 3
’21 1 (3) (4) 4 (2)
’20 0 2 4 1 7
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jan Apr Jul Oct Year
’26 3 2 6 — —
’25 (1) 4 6 1 10
’24 4 8 2 6 20
’23 0 0 5 5 11
’22 (3) (4) (2) 6 (4)
’21 0 (5) (4) 1 (9)
’20 0 2 3 1 5
Fiscal quarters ending in the months shown.

EPS $

Jan Apr Jul Oct Year
’26 0.01 0.00 0.09 — —
’25 (0.02) (0.03) 0.01 (0.33) (0.44)
’24 0.00 0.00 0.01 (0.04) (0.04)
’23 (0.04) (0.02) (0.03) (0.29) (0.39)
’22 (0.11) (0.11) (0.03) (0.64) (0.89)
’21 (0.02) (0.02) (0.03) (0.07) (0.67)
’20 (0.02) (0.02) 0.01 (0.11) (0.02)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to October

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — 1.80 0.65 2.78 1.30 1.03 1.57 1.64

Analyst estimates 2026–2028

Powerpack
High — — — 7.10 3.30 13.29 5.89 2.30 3.62 4.06
People
People Employees — — — — — 996 1,300 1,550 1,550 1,832
Revenue/emp, $m — 0.00 0.00 0.00 0.00 0.14 0.21 0.23 0.25 0.23
Income, $m
Income, $m Revenue — 8 7 24 62 144 277 362 384 424
Gross margin, % — 46.83 0.98 36.16 37.00 35.33 28.29 26.93 27.28 25.85
EBT — 0 (5) (20) (5) (28) (57) (36) (3) (37)
EBT margin, % — 5.62 (68.90) (86.28) (7.36) (19.75) (20.67) (9.96) (0.84) (8.66)
Net income — 0 (3) (20) (5) (28) (55) (30) (3) (37)
Depreciation — 0 0 1 5 19 23 24 19 17
Per share, $
Per share, $ Revenue — 0.62 0.53 0.12 0.27 3.39 4.42 4.86 4.82 5.16
Earnings — 0.02 (0.27) (0.10) (0.02) (0.67) (0.89) (0.39) (0.04) (0.44)
Cash flow — 0.06 (0.53) (0.06) 0.03 (0.05) 0.06 0.21 0.33 0.21
Capex — 0.00 0.00 (0.04) (0.01) (0.15) (0.11) (0.06) (0.08) (0.09)
Free cash flow — 0.06 (0.53) (0.10) 0.02 (0.21) (0.06) 0.15 0.25 0.12
Book value — (0.60) 1.42 0.04 0.04 2.85 2.01 1.33 1.34 0.89
Shares, m — 13 13 198 229 42 63 74 80 82
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — 0.00 0.00 0.00 0.51 1.70 0.33 0.30 0.58 0.60
P/B — 79.07 79.07 79.07 4.08 2.03 0.73 1.09 2.10 3.48
EV/Sales — 0.00 0.00 0.00 0.99 1.86 0.43 0.37 0.59 0.69
EV/FCF — 0.00 0.00 0.00 8.58 (30.46) (33.98) 12.37 11.61 30.10
Cash, $m
Cash, $m Operating cash flow — 1 (7) (11) 7 (2) 3 15 26 17
Capex — 0 (3) (8) (2) (7) (7) (5) (7) (7)
Free cash flow — 1 (7) (19) 5 (9) (4) 11 20 10
Balance, $m
Balance, $m Working capital — (8) 11 1 (6) 4 3 8 18 26
Total debt — 14 0 15 32 35 48 48 38 70
Net debt — 13 (6) 15 26 23 29 26 3 36
Shareholders’ equity — (7) 18 7 9 121 126 99 107 73
Returns, %
Returns, % ROA — 1.62 (34.87) (78.43) (11.45) (22.49) (27.24) (15.08) (1.80) (16.85)
ROIC — 0.00 0.00 (42.85) 1.06 (5.50) (22.71) (15.36) 2.09 (5.89)
ROE — 4.45 (66.85) (158.98) (59.84) (43.00) (45.18) (25.91) (3.09) (40.19)
Negative figures in brackets.

All 10 years →

Fiscal years to Oct 2025 · latest quarter Jul 2026 · fundamentals updated 2 Oct 2026

Charts ten years each

High Tide Inc. vs peers in Pharmaceutical Retailers (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
HITI High Tide Inc. $228.2M — (loss-making) 92.0× +30.72% (above 0%: growing) +800.00% (above 0%: growing) −7.91% (below 0%: shrinking) 26.53% 4.38%
PETS PetMed Express, Inc. $26.4M — (loss-making) 24.0× −19.86% (below 0%: shrinking) n/m +38.60% (above 0%: growing) 27.63% (15.19%) Compare
MEDS DataMeds AI, Inc $12.8M — (loss-making) — −77.15% (below 0%: shrinking) n/m −41.85% (below 0%: shrinking) 10.24% (412.67%) Compare
SCNX Scienture Holdings, Inc. $5.6M — (loss-making) — (loss-making) +3,235.92% (above 0%: growing) n/m −53.98% (below 0%: shrinking) 97.73% (785.71%) Compare
POM Pomdoctor Limited - Sponsored ADR $5.0M — — — — — — — Compare
RDGT Ridgetech Inc. $3.0M — (loss-making) — (loss-making) +113.14% (above 0%: growing) n/m +4,848.31% (above 0%: growing) 22.81% 0.00% Compare
MDVLQ MedAvail Holdings, Inc. $2.9M — (loss-making) — (loss-making) −25.41% (below 0%: shrinking) n/m +66.32% (above 0%: growing) 43.95% (1,099.75%) Compare
BIMI BIMI Holdings Inc. $170.0K — (loss-making) — −48.85% (below 0%: shrinking) n/m +28.06% (above 0%: growing) 4.57% (124.83%) Compare
Median of peers $5.0M — — −22.63% — +33.33% 25.22% (268.75%)

All 8 Pharmaceutical Retailers stocks →

High Tide Inc. (HITI) key facts

  • Strength: High Tide Inc.’s revenue for fiscal 2025 (year ended October 2025) was $424.0 million, up 10.5% from fiscal 2024.
  • High Tide Inc. (HITI) is a Pharmaceutical Retailers company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, HITI traded at $2.57, a market capitalization of $228.2 million.
  • Return on equity was −40.2% and debt-to-equity 0.93.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 1.52 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 2, 2026.

High Tide Inc. (HITI) Latest News

17 Sep

Impact 4 · transcript
stockrow.com/HITI · Data as of Oct 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com